Previous 10 | Next 10 |
2024-06-18 11:06:42 ET More on AtriCure AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript AtriCure Q1 2024 Earnings Preview AtriCure upgraded at Oppenheimer on valuation Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for...
2024-05-19 07:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-16 16:41:26 ET Summary We recap Q1 developments from Pulse Biosciences, Inc. The FDA has cleared the company's percutaneous electrode system, while the surgical clamp device for cardiac indications is still in the preclinical trial phase. Pulse Biosciences is making pr...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healt...
2024-05-02 10:00:43 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...
2024-05-02 01:48:02 ET AtriCure, Inc. (ATRC) Q1 2024 Earnings Conference Call May 1, 2024 16:30 ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference C...
2024-05-01 16:27:26 ET More on AtriCure AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript AtriCure Q1 2024 Earnings Preview AtriCure upgraded at Oppenheimer on valuation Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for...
Worldwide revenue of $108.9 million – an increase of 16.4% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, t...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...